A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women

Menopause

Volumn 14, Issue 6, 2007, Pages 985-994

  Shifren, Jan L ^a,b   Desindes, Sophie ^c   McIlwain, Marilyn ^d   Doros, Gheorghe ^e   Mazer, Norman A ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d Watson Laboratories Inc   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal; Androgen; Estrogen; Menopause; Thyroid; Transdermal

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTRADIOL; HYDROCORTISONE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROID HORMONE; THYROXINE; THYROXINE BINDING GLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSAL SYNDROME; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; CARRIER PROTEINS; CROSS-OVER STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTERONE; TESTOSTERONE; THYROXINE; TREATMENT OUTCOME;

EID: 36048982140     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31803867a     Document Type: Article

References (52)

1. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;291:1610-1620.
2. Good WR, John VA, Ramirez M, Higgins JE. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group. Climacteric 1999;2:29-36.
3. Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 2000;6:419-426.
4. Notelovitz M, John VA, Good WR. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 2002;9:343-353.
5. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-1620.
6. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991;73:275-280.
7. Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980;51:620-625.
8. Mazer NA. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid 2004;14(Suppl 1):S27-S34.
9. Mazer NA. Effect of estrogen replacement therapy on testosterone levels in women: differences between oral and transdermal routes of administration. Suppl OBG Manage 2001;September:10-13.
10. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 1989;10:232-274.
11. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
12. Esoterix, Inc. Laboratory services, expected values & S.I. unit convesion tables. Available at: http://www.esoterix.com/files/expected_values. pdf. Accessed January 13, 2006.
13. 1) and cortisol (C) in men and women. In: The Endocrine Society: Program and Abstracts 88th Annual Meeting, June 24-27, Boston, MA. Chevy Chase, MD: Endocrine Society Press, 2004:536. Poster P2-551.
14. Williamson D. Box and whisker plots: getting Microsoft Excel to plot them for you. Available at: http://www.duncanwil.co.uk/boxplot.html. Accessed January 26, 2006.
15. Levene H. Robust tests for equality of variances. In: Olkin I, Ghurye SG, Hoeffding W, Madow WG, Mann HB, eds. Contributions to Probability and Statistics. Stanford, CA: Stanford University Press, 1960:278-292.
16. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
17. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965;21:467-480.
18. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-268.
19. Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 1999;72:389-397.
20. Wilcox JG, Stanczyk FZ, Morris RS, Gentzschein E, Lobo RA. Biologic effects of 17 α-dihydroequilin sulfate. Fertil Steril 1996;66:748-752.
21. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-258.
22. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687-2693.
23. Serin IS, Ozcelik B, Basbug M, Aygen E, Kula M, Erez R. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels. Eur J Obstet Gynecol Reprod Biol 2001;99:222-225.
24. Castelo-Branco C, Martinez de Osaba MJ, Vanrezc JA, Fortuny A, Gonzalez-Merlo J. Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas 1993;17:101-111.
25. Castelo-Branco C, Martinez de Osaba MJ, Fortuny A, Iglesias X, Gonzalez-Merlo J. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995;40:556-560.
26. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43.
27. Stomati M, Hartmann B, Spinetti A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest 1996;19:535-541.
28. Gower BA, Nyman L. Associations among oral estrogen use, free testosterone concentration, and lean body mass among postmenopausal women. J Clin Endocrinol Metab 2000;85:4476-4480.
29. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001;344:1743-1749.
30. Marqusee E, Braverman LE, Lawrence JE, Carroll JS, Seely EW. The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab 2000;85:4407-4410.
31. Genazzani AD, Gamba O, Petraglia F. Estrogen replacement therapy modulates spontaneous GH secretion but does not affect GH-RH-induced GH response and low T3 syndrome in women with hypothalamic amenorrhea associated to weight-loss. J Endocrinol Invest 1998;21:353-357.
32. Pluchino N, Genazzani AD, Bernardi F, et al. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Gynecol Endocrinol 2005;20:144-149.
33. Burleson MH, Malarkey WB, Cacioppo JT, et al. Postmenopausal hormone replacement: effects on autonomic, neuroendocrine, and immune reactivity to brief psychological stressors. Psychosom Med 1998;60:17-25.
34. Tazuke S, Khaw KT, Barrett-Connor E. Exogenous estrogen and endogenous sex hormones. Medicine (Baltimore) 1992;71:44-51.
35. Williams CD, Dobridge JD, Meyer WR, Hackney AC. Effects of the route of estrogen administration and exercise on hormonal levels in postmenopausal women. Fertil Steril 2002;77:1118-1124.
36. Kudielka BM, Schmidt-Reinwald AK, Hellhammer DH, Kirschbaum C. Psychological and endocrine responses to psychosocial stress and dexamethasone/corticotropin-releasing hormone in healthy postmenopausal women and young controls: the impact of age and a two-week estradiol treatment. Neuroendocrinology 1999;70:422-430.
37. Puder JJ, Freda PU, Goland RS, Wardlaw SL. Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J Clin Endocrinol Metab 2001;86:2403-2408.
38. Cucinelli F, Soranna L, Barini A, et al. Estrogen treatment and body fat distribution are involved in corticotropin and cortisol response to corticotropin-releasing hormone in postmenopausal women. Metabolism 2002;51:137-143.
39. Casson PR, Elkind-Hirsch KE, Buster JE, Hornsby PJ, Carson SA, Snabes MC. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 1997;90:995-998.
40. Perrone G, Falaschi P, Capri O, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 1994;39:202-207.
41. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York, NY: Marcel Dekker, 1982:330.
42. Pardridge WM, Mietus LJ. Transport of protein-bound steroid hormones into liver in vivo. Am J Physiol 1979;237:E367-E372.
43. Longcope C, Hui SL, Johnston CC Jr. Free estradiol, free testosterone, and sex hormone-binding globulin in perimenopausal women. J Clin Endocrinol Metab 1987;64:513-518.
44. Bianchi R, Iervasi G, Pilo A, et al. Role of serum carrier proteins in the peripheral metabolism and tissue distribution of thyroid hormones in familial dysalbuminemic hyperthyroxinemia and congenital elevation of thyroxine-binding globulin. J Clin Invest 1987;80:522-534.
45. Bright GM. Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J Clin Endocrinol Metab 1995;80:770-775.
46. Mazer NA. Testosterone deficiency in women: etiologies, diagnosis, and emerging treatments. Int J Fertil Womens Med 2002;47:77-86.
47. Vermeulen A, Ando S. Metabolic clearance rate and interconversion of androgens and the influence of the free androgen fraction. J Clin Endocrinol Metab 1979;48:320-326.
48. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589.
49. Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause 2006;13:37-45.
50. Davis SR, van der Mooren MJ, van Lunsen RH, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13:387-396.
51. Shifren JL. Is testosterone or estradiol the hormone of desire? A novel study of the effects of testosterone treatment and aromatase inhibition in postmenopausal women. Menopause 2006;13:8-9.
52. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534.